Medical Cannabis: Miracle or Myth?

Blair Henry  
*University of Toronto, Canada*

Arnav Agarwal  
*University of Toronto, Canada*

Edward Chow  
*University of Toronto, Canada*

Hatim A. Omar  
*University of Kentucky, hatim.omar@uky.edu*

Joav Merrick  
*University of Kentucky*

Click here to let us know how access to this document benefits you.

Follow this and additional works at: [https://uknowledge.uky.edu/pediatrics_facpub](https://uknowledge.uky.edu/pediatrics_facpub)

Part of the [Food and Drug Law Commons](https://uknowledge.uky.edu/fdcl), [Pain Management Commons](https://uknowledge.uky.edu/pmg), and the [Pharmacy and Pharmaceutical Sciences Commons](https://uknowledge.uky.edu/pharm)

Repository Citation

Henry, Blair; Agarwal, Arnab; Chow, Edward; Omar, Hatim A.; and Merrick, Joav, "Medical Cannabis: Miracle or Myth?" (2016). *Pediatrics Faculty Publications*. 253.  
[https://uknowledge.uky.edu/pediatrics_facpub/253](https://uknowledge.uky.edu/pediatrics_facpub/253)

This Editorial is brought to you for free and open access by the Pediatrics at UKnowledge. It has been accepted for inclusion in Pediatrics Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Medical Cannabis: Miracle or Myth?

Notes/Citation Information
Published in *Journal of Pain Management*, v. 9, issue 4, p. 341-343.

© Nova Science Publishers, Inc.

The copyright holders have granted the permission for posting the article here.

This editorial is available at UKnowledge: https://uknowledge.uky.edu/pediatrics_facpub/253
Medical cannabis: Miracle or myth?

Blair Henry1,*, D. Bioethics, Arnava Agarwal1, MD(C), Edward Chow1, MBBS, Hatim A Omar2, MD, FAAP, and Joav Merrick2-6, MD, MMedSc, DMSc
1Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
2Division of Adolescent Medicine and Young Parents Program, Kentucky Children’s Hospital, UK Healthcare, Department of Pediatrics, University of Kentucky College of Medicine, Lexington, Kentucky, USA
3National Institute of Child Health and Human Development, Jerusalem
4Office of the Medical Director, Health Services, Division for Intellectual and Developmental Disabilities, Ministry of Social Affairs and Social Services, Jerusalem
5Division of Pediatrics, Hadassah Hebrew University Medical Center, Mt Scopus Campus, Jerusalem, Israel
6Center for Healthy Development, School of Public Health, Georgia State University, Atlanta, USA

Introduction

Cannabis has a long history of medicinal use, dating back thousands of years (1). However, with the discovery of morphine, hypodermic needles and other fast acting synthetic opioids in the nineteenth and the turn of the twentieth century - cannabis use declined as a medication (2).

For most of the past six decades, cannabis has been considered a recreational drug, and was considered illegal in many jurisdictions. Yet in the past few years its association with medicine has made a dramatic comeback. As illustrated in figure 1, over the past six years (2010-2016) the terms “medical cannabis” and “medical marijuana” has seen a 4- to 5-fold increase in references based on a historical trend analysis of the terms noted in the PubMed database. It would appear that the term medical cannabis is most often used over medical marijuana, in the emerging literature.

In the past several years, claims on the potential for cannabis to treat, cure and prevent a number of diseases and conditions has led some to query whether these claims are overstated.

A game changer for medical cannabis has been the ability to consume it without a need to actually inhale it along with other negative products of combustion. Newer technologies that allow for the vaporization of the full plant has made it less of a health concern (3).

Noticeably the evidence on medical cannabis is lacking in both quality and quantity. To date most of the research has been conducted in Israel, however, with cannabis set to be legalized for use in Canada (4) and in a recent move in the United States, by the Obama administration (5), to remove barriers should allow researchers greater access to medical cannabis for testing in well-designed clinical trials.
In Canada, the federal marijuana regulations were updated in the summer of 2016 with the introduction of the Access to Cannabis for Medical Purposes Regulations (ACMPR). The aim of this newly update regulation (ACMPR) is to treat marijuana like other psychoactive drugs used for medical purposes. Many of the Colleges (eight provincial) in Canada prohibit or at best strongly discourage its members from dispensing, providing or accepting delivery of marijuana for medical purposes (6). Of major concern for most Colleges has been a lack of good evidence on both medical risks and therapeutic benefits of marijuana- intimating that physicians’ currently prescribing cannabis may be falling short of a fulsome informed consent process.

The typical recommendation for Canadian physicians is that medical cannabis should not be a first line therapy and that documentation should outline that conventional therapies were attempted but were not successful (6). The legal defense organization for physicians practicing in Canada- the Canadian Medical Protective Association (CMPA), updated its guidance document following the passing of ACMPR regulations- a cursory read through this document quickly identifies a less than positive endorsement for physicians, highlighting mainly potential risks and limitations to physicians potentially interested in adding medical cannabis to their treatment recommendations.

As the medical community has been slow to start-noticeable in the grey literature is the proliferation of website by patient and advocacy groups making claims that cannabis has the potential to treat ailments and symptoms ranging from AIDS related illness, Asperger’s, Bulimia, carpal tunnel syndrome to whiplash- making the differentiation between the miraculous and mere hype all the more challenging to identify (7-9).

References


